Exicure (NASDAQ:XCUR – Get Free Report) and Protalix BioTherapeutics (NYSE:PLX – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, risk, analyst recommendations, valuation, dividends and profitability.
Profitability
This table compares Exicure and Protalix BioTherapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Exicure | N/A | -237.91% | -61.98% |
| Protalix BioTherapeutics | -21.03% | -30.89% | -11.74% |
Analyst Ratings
This is a summary of current ratings and price targets for Exicure and Protalix BioTherapeutics, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Exicure | 1 | 0 | 0 | 0 | 1.00 |
| Protalix BioTherapeutics | 0 | 0 | 1 | 0 | 3.00 |
Protalix BioTherapeutics has a consensus target price of $12.00, suggesting a potential upside of 313.79%. Given Protalix BioTherapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Protalix BioTherapeutics is more favorable than Exicure.
Institutional and Insider Ownership
42.8% of Exicure shares are held by institutional investors. Comparatively, 16.5% of Protalix BioTherapeutics shares are held by institutional investors. 52.8% of Exicure shares are held by insiders. Comparatively, 6.7% of Protalix BioTherapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
Exicure has a beta of 3.83, meaning that its share price is 283% more volatile than the S&P 500. Comparatively, Protalix BioTherapeutics has a beta of 0.01, meaning that its share price is 99% less volatile than the S&P 500.
Earnings & Valuation
This table compares Exicure and Protalix BioTherapeutics”s revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Exicure | N/A | N/A | -$4.95 million | ($0.83) | -1.08 |
| Protalix BioTherapeutics | $84.69 million | 2.89 | $8.31 million | $0.25 | 11.60 |
Protalix BioTherapeutics has higher revenue and earnings than Exicure. Exicure is trading at a lower price-to-earnings ratio than Protalix BioTherapeutics, indicating that it is currently the more affordable of the two stocks.
Summary
Protalix BioTherapeutics beats Exicure on 8 of the 13 factors compared between the two stocks.
About Exicure
Exicure, Inc. is a biotechnology company historically focused on developing nucleic acid-based therapeutics. Its research has centered on spherical nucleic acid (SNA) technology, a platform designed to deliver genetic material into cells and influence disease-related gene activity. The company has pursued potential treatments for conditions including rare genetic disorders and cancer. Its work has included research into therapies intended to address diseases with limited treatment options. Exicure was based in Chicago, Illinois.
About Protalix BioTherapeutics
Protalix BioTherapeutics is an Israel-based biopharmaceutical company that develops and manufactures recombinant therapeutic proteins using its proprietary plant-cell expression system, ProCellEx. The company focuses on treatments for rare and chronic diseases and was founded in 1993. Its products include Elelyso (taliglucerase alfa), an enzyme replacement therapy for Gaucher disease, and Elfabrio (pegunigalsidase alfa), an enzyme replacement therapy for Fabry disease. Protalix developed Elfabrio in collaboration with Chiesi Global Rare Diseases; commercialization and distribution are handled through partner arrangements in multiple markets.
Receive News & Ratings for Exicure Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exicure and related companies with MarketBeat.com's FREE daily email newsletter.
